



## COMUNICATO STAMPA

### **NEOPHARMED GENTILI S.P.A. ANNUNCIA UN’OFFERTA DI SENIOR SECURED FLOATING RATE NOTES CON SCADENZA 2033**

*Milano, 15 giugno 2026* – Neopharmed Gentili S.p.A., società per azioni costituita ai sensi della legge italiana (l’**“Emittente”**), ha lanciato un’offerta (l’**“Offerta”**) di *Senior Secured Floating Rate Notes* con scadenza 2033 (le **“Notes”**) per un ammontare complessivo pari a €425 milioni.

I proventi dell’Offerta, subordinatamente al suo perfezionamento, verranno destinati, congiuntamente alle disponibilità liquide dell’Emittente, (i) al rimborso integrale delle *Senior Secured Floating Rate Notes* con scadenza 2030 emesse dall’Emittente in data 8 aprile 2024 per un ammontare complessivo pari a €400 milioni e interessi maturati e non corrisposti alla data di rimborso (le **“Notes Esistenti”**), (ii) ad una distribuzione in favore della società controllante dell’Emittente, finalizzata al rimborso parziale delle *Senior Secured Floating Rate Payment-In-Kind Notes* con scadenza 2031, emesse dalla società controllante in data 29 settembre 2025, e (iii) al pagamento delle commissioni e delle spese sostenute in relazione all’Offerta. In data odierna è stata trasmessa ai portatori delle Notes Esistenti una comunicazione di rimborso, subordinato al perfezionamento dell’Offerta.

Subordinatamente al perfezionamento dell’Offerta, le Notes verranno quotate sul Listino Ufficiale del Luxembourg Stock Exchange e ammesse alla negoziazione sull’Euro MTF Market.

Vengono riportate di seguito, a beneficio dei potenziali investitori delle Notes, le informazioni relative al *recent trading* dell’Emittente.

#### **Recent Trading**

Based on preliminary results derived from our unaudited management accounts and other information currently available, we estimate that our Total Revenues for the four months ended April 30, 2026, increased relative to the corresponding period in 2025. In particular, our Total Revenues increased by approximately €27.3 million, or 28.0%, from approximately €97.6 million for the four months ended April 30, 2025, to approximately €124.9 million for the four months ended April 30, 2026, including the positive contribution of revenues from sales of ORLADEYO, which amounted to approximately €16.9 million. The estimated increase in Total Revenues was mainly driven by the contribution of (i) specialty and primary care products acquired during the year (i.e., Plasil, Primperan, Steglujan and Steglatro), and (ii) the BioCryst European Group following the completion of the BioCryst Acquisition on October 1, 2025. Total Revenues for the four months ended April 30, 2026 benefited from the cancellation of the 1.83% payback applied to Class A products, resulting in savings of approximately €1.9 million.

*The preliminary financial results presented above are derived from our unaudited management reporting data. This information has not been audited or reviewed, nor have any procedures been performed by our independent auditors with respect to such unaudited financial information for the purpose of its inclusion in this announcement and, accordingly, they have not expressed an opinion or*

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

*provided any form of assurance with respect thereto for the purpose of this announcement. Furthermore, such unaudited financial information does not take into account any circumstances or events occurring after the period to which it refers. Accordingly, you should not place undue reliance on it, and no opinion or any other form of assurance is provided with respect thereto. Our preliminary financial results are based upon a number of assumptions and judgments that are subject to inherent uncertainties and are subject to change and are not intended to be a comprehensive statement of our financial or operational results for the four months ended April 30, 2026 and 2025. The preliminary financial results presented above may change and those changes may be material.*

\*\*\*

Neopharmed Gentili è un'azienda farmaceutica nata in Italia e storicamente radicata nel proprio territorio, in forte espansione oltre i confini nazionali grazie ad una consolidata ed affidabile esperienza nelle operazioni di M&A e Licensing, specialmente con partner multinazionali. Ricerca, responsabilità e cura sono i pilastri che guidano la mission di Neopharmed Gentili di migliorare la salute e la qualità di vita di pazienti, caregiver e personale sanitario. L'aspirazione di Neopharmed Gentili è di aiutare le persone a vivere una vita sana e più longeva possibile, agendo con valore etico e precisione scientifica, e offrendo soluzioni ad alto valore terapeutico.

## **Investor Relations Contact**

### **Neopharmed Gentili S.p.A.**

*Investor Relations*

[investors@neogen.it](mailto:investors@neogen.it)

\*\*\*

*This press release contains inside information relating to the Issuer within the meaning of Regulation (EU) 596/2014 and relevant implementing rules and regulations.*

*This press release is for information purposes only and does not constitute any offer to sell or the solicitation of an offer to buy any security in the United States or in any other jurisdiction. The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or applicable state or foreign securities laws and may not be offered or sold in the United States without registration under federal or applicable state securities laws or an applicable exemption from such registration requirements.*

*The Notes will be offered (a) in the United States to "qualified institutional buyers" as defined in Rule 144A under the Securities Act and (b) outside the United States (i) in offshore transactions in accordance with Regulation S under the Securities Act, (ii) if resident in a Member State of the European Economic Area, to "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the "Prospectus Regulation") and any relevant implementing measure in each Member State of the European Economic Area and (iii) if a resident of the United Kingdom, to "qualified investor" within the meaning of paragraph 15 of schedule 1 to the Public Offers and Admissions to Trading Regulations 2024 (the "Public Offers Regulation").*

*This press release does not constitute an offer to the public in Italy of financial products, as defined under Article 1, paragraph 1, letter (t) of legislative decree of February 24, 1998, no. 58, as amended (the "Italian Financial Act"). The Notes cannot be offered, sold or delivered, directly or indirectly, in Italy either on the primary or on the secondary market to any natural persons nor to entities other than qualified investors (investitori qualificati) as referred to in Article 2(e) of the Prospectus Regulation or unless in any circumstances which are exempt from the rules on public offerings pursuant to Article 1 of the Prospectus Regulation and the implementing regulations issued by the Commissione Nazionale per le Società e la Borsa, the Italian securities and financial markets regulator ("CONSOB"), including CONSOB Regulation No. 20307 of February 15, 2018, as amended, Article 34-ter, paragraph 1, letter (b) of CONSOB Regulation no. 11971 of May 14, 1999, as amended, implementing Article 100 of the Italian Financial Act, and the applicable Italian laws and regulations.*

*This press release is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, (iii) are outside the United Kingdom or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.*

*The offering memorandum prepared in connection with the Offering has not been and will not be approved by CONSOB, the Financial Conduct Authority or any other competent authority.*

*Manufacturer target market (MIFID II product governance; UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No key information document*

*required by the PRIIPs Regulation has been prepared as the Notes are not available to retail investors in the EEA. No disclosure document required by the FCA Product Disclosure Sourcebook (“DISC”) for offering, selling or distributing the Notes or otherwise making them available to retail investors in the UK has been or will be prepared and therefore offering, selling or distributing the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024, as applicable.*

*This press release may include forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts, including, without limitation, those regarding the future financial position and results of operations, strategies, plans, objectives, goals and targets, future developments in the markets in which the Issuer participates or is seeking to participate or anticipated regulatory changes in the markets in which the Issuer operates or intends to operate. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “forecast”, “guidance”, “intend”, “may”, “plan”, “potential”, “predict”, “projected”, “should” or “will” or the negative of such terms or other comparable terminology.*

*By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and are based on numerous assumptions. Our actual results of operations, including our financial condition and liquidity and the development of the industries in which we operate, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this press release. In addition, even if our results of operations, including our financial condition and liquidity and the development of the industries in which we operate, are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods.*